News
CHMP Recommends AstraZeneca’s Trixeo for Asthma, Enhertu for Breast Cancer
The Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Trixeo for the maintenance treatment of asthma and Enhertu, in combination with pertuzumab, for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer in the European Union (EU).
imphoenix82
- July 25, 2026
- 0 Comments
- 147 Views
-
